Dobutamine-Induced Myoclonus in a Patient With Advanced Heart Failure and Chronic Kidney Disease

Alexander Y Lee; Shiva Barforoshi; Alvin Singh; Ritesh Shrestha; James Ha; Michelle Kittleson

doi:10.1016/j.jaccas.2024.102255

Dobutamine-Induced Myoclonus in a Patient With Advanced Heart Failure and Chronic Kidney Disease

JACC Case Rep. 2024 Feb 16;29(6):102255. doi: 10.1016/j.jaccas.2024.102255. eCollection 2024 Mar 20.

Authors

Alexander Y Lee¹, Shiva Barforoshi², Alvin Singh³, Ritesh Shrestha⁴, James Ha⁵, Michelle Kittleson⁴

Affiliations

¹ Department of Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
² Department of Internal Medicine, Harbor-UCLA Medical Center, Torrance, California, USA.
³ Department of Neurology, UCLA Ronald Reagan Medical Center, Los Angeles, California, USA.
⁴ Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
⁵ Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Abstract

Dobutamine is a positive inotropic agent often used in treatment of cardiogenic shock. Although there are well-documented adverse effects, dobutamine-induced myoclonus is a rarely reported phenomenon. Our case offers a direct and temporally related description of myoclonus, with onset observed within hours of dobutamine initiation and complete resolution within minutes of discontinuation.

Keywords: physical examination; systolic heart failure; treatment.

Publication types

Case Reports